Evidence map›Paper›PMID 32731813›Full record

ArticleThe American journal of psychiatry2020

Identification of a Signaling Mechanism by Which the Microbiome Regulates Th17 Cell-Mediated Depressive-Like Behaviors in Mice.

Eva M Medina-Rodriguez, Derik Madorma, Gregory O'Connor, Brittany L Mason, Dongmei Han, Sapna K Deo, Mark Oppenheimer, Charles B Nemeroff, Madhukar H Trivedi, Sylvia Daunert and 1 more

Open access · greenAbstract read
In one paragraph

Article in The American journal of psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 117 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. The emerging role of T cells in depression.Frontiers in psychiatry · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Zebrafish (Ecology and evolution · 2024
    Article
  16. Article
  17. Zebrafish (bioRxiv : the preprint server for biology · 2024
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Eva M Medina-RodriguezDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Derik MadormaDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Gregory O'ConnorDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Brittany L MasonDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Dongmei HanDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Sapna K DeoDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Mark OppenheimerDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Charles B NemeroffDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Madhukar H TrivediDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Sylvia DaunertDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Eléonore BeurelDepartment of Psychiatry and Behavioral Sciences (Medina-Rodriguez, Han, Oppenheimer, Beurel), Department of Biochemistry and Molecular Biology (Madorma, O'Connor, Deo, Daunert, Beurel), the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute (Madorma, O'Connor, Deo, Daunert), and the University of Miami Clinical and Translational Science Institute (Daunert), Miller School of Medicine, University of Miami, Miami; Department of Psychiatry, Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas (Mason, Trivedi); and Department of Psychiatry, Mulva Clinic for Neurosciences, University of Texas Dell Medical School in Austin (Nemeroff).
Dr. John T. Macdonald Foundation · US

Funding

Th17 cells as a new therapeutic target for depressionR01MH104656 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BEUREL, ELEONORE · 2015 to 2024
$3.8M
PHOTOPROTEINS AS LABELS IN BIOLUMINESCENCE ASSAYSR01GM047915 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DAUNERT, SYLVIA · 2000 to 2013
$3.5M
The microbiota, a possible link between Th17 cells and depressionR01MH110415 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BEUREL, ELEONORE · 2017 to 2021
$1.5M
Sensitive Detection of Viral Persistency Using Bioluminescent Stem-Loop ProbesR01GM114321 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DEO, SAPNA K · 2015 to 2019
$1.5M
Portable, Rapid, Multiplexed Flow strip Test for BacteriaR01GM127706 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI DAUNERT, SYLVIA, DEO, SAPNA K · 2018 to 2021
$1.2M
NIGMS NIH HHS R01 GM047915NIGMS NIH HHS R01 GM114321NIGMS NIH HHS R01 GM127706NIMH NIH HHS R01 MH104656NIMH NIH HHS R01 MH110415
6 · The paper itself

Abstract

objectiveMicrobiota dysbiosis has been linked to major depressive disorder, but the mechanisms whereby the microbiota modulates mood remain poorly understood. The authors tested whether specific changes in the microbiome modulate depressive-like behaviors.

methodsStools from learned helpless, non-learned helpless, and non-shocked mice were analyzed by V4 16S RNA sequencing to identify gut bacteria associated with learned helplessness and to quantify the level of the quorum-sensing molecule autoinducer-2 (AI-2). T cells were analyzed by flow cytometry, and serum amyloid proteins (SAA) were analyzed by quantitative real-time polymerase chain reaction. Fecal transfer approach and administration of oleic acid and AI-2 were used to determine the effects of the microbiome and quorum-sensing molecules on depressive-like behaviors.

resultsMice deficient in segmented filamentous bacteria (SFB) were resilient to the induction of depressive-like behavior, and were resensitized when SFB was reintroduced in the gut. SFB produces the quorum-sensing AI-2 and promotes the production of SAA1 and SAA2 by the host, which increases T helper 17 (Th17) cell production. Th17 cells were required to promote depressive-like behaviors by AI-2, as AI-2 administration did not promote susceptibility to depressive-like behaviors or SAA1 and SAA2 production in Th17-deficient mice after stress. Oleic acid, an AI-2 inhibitor, exhibited antidepressant properties, reducing depressive-like behavior, intestinal SAA1 and SAA2 production, and hippocampal Th17 cell accumulation. Stool samples from 10 people with current depressive symptoms and 10 matched healthy control subjects were analyzed as well. Patients with current major depressive disorder exhibited increased fecal interleukin 17A, SAA, and SFB levels.

conclusionsThe study results reveal a novel mechanism by which bacteria alter mood.

Indexed as

AdultAnimalsDepressionDisease Models, AnimalFecesFemaleFlow CytometryGastrointestinal MicrobiomeHelplessness, LearnedHumansInterleukin-17Major Depressive DisorderMaleMiceMice, Inbred C57BLMiddle AgedIL17A protein, humanInterleukin-17RNA, Ribosomal, 16SSerum Amyloid A ProteinAutoinducer-2DepressionMicrobiomeTh17 Cells

Identifiers

PMID32731813
PMCPMC7647050
OpenAlexW3046220904

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.